CMTM6 overexpression confers trastuzumab resistance in HER2-positive breast cancer
Abstract Human epidermal growth factor receptor 2-positive (HER2+) breast cancer is characterized by invasive growth, rapid metastasis and chemoresistance. Trastuzumab is an effective treatment for HER2+ breast cancer; however, trastuzumab resistance leads to cancer relapse and metastasis. CKLF-like...
Gardado en:
| Principais autores: | , , , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
BMC
2023-01-01
|
| Series: | Molecular Cancer |
| Assuntos: | |
| Acceso en liña: | https://doi.org/10.1186/s12943-023-01716-y |
| Tags: |
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|